#USA #Immunotherapy #Cold Spring Harbor #ANRE

Unraveling the Connection Between Cancer and Brain Disease

Recent findings from Cold Spring Harbor Laboratory (CSHL) unveil a compelling relationship between cancer's immune responses and neurological disorders. Every day, our bodies generate hundreds of billions of new cells, with many undergoing mutations. This raises an intriguing question: If cancer stems from these mutations, why don’t we all develop this disease?

At the same time, conditions like lupus and multiple sclerosis suddenly emerge without explanation, leaving scientists puzzled about their triggers. CSHL's latest research published in Nature posits that these two medical enigmas could be interconnected. Sam Kleeman, who led the study as a recent CSHL Ph.D. graduate, suggests that our immune system is equipped with antibodies capable of combating tumors while simultaneously attacking the brain.

The Study and Its Groundbreaking Findings

Kleeman’s team specifically investigated anti-NMDA receptor encephalitis (ANRE), a debilitating autoimmune brain disease highlighted in Susannah Cahalan’s bestselling book, Brain on Fire. In ANRE, the immune system erroneously targets proteins in the brain, called NMDA receptors, leading to severe symptoms such as psychosis, insomnia, and seizures. Alarmingly, many ANRE patients also have tumors that produce NMDA receptors externally.

Using a mouse model of breast cancer, the researchers traced antibodies from their precursors at birth, studying their evolution and effectiveness in tumor reduction. Their findings revealed that mice exhibiting strong antibody responses experienced spontaneous tumor shrinkage. However, this same antibody infusion into the brains of healthy mice triggered seizures and increased body temperatures, closely resembling symptoms in ANRE patients.

A pivotal breakthrough involved CSHL Professor Hiro Furukawa, an expert in molecular neuroscience. Using cryo-electron microscopy (cryo-EM), he discovered that some antibodies stimulated NMDA receptors, while others inhibited them. This dual effect implies that an immune response directed at a tumor could generate antibodies with opposing impacts on the brain. Understanding the balance between protective and harmful antibodies could lead to treatments that harness the immune system’s capabilities against cancer while limiting neurological harm.

Moving Towards Clinical Applications

With these insights, the researchers shifted their focus towards clinical applications. Collaborating with Northwell Health, they discovered that NMDA receptor proteins are often produced by tumors in patients with triple-negative breast cancer—a particularly resistant form of cancer to conventional therapies. Notably, around 15% of these patients developed antibodies targeting NMDA receptors, and those with such antibodies typically exhibited improved clinical outcomes. This suggests their immune systems were actively engaging in the fight against cancer.

“This knowledge equips us to start designing antibody-based medications to benefit patients with triple-negative breast cancer,” states CSHL Associate Professor Tobias Janowitz, who supervised the study alongside Furukawa. “While cancer remains a perplexing issue, our holistic approach to the body's reaction could lead to breakthroughs in understanding long-standing biomedical mysteries.”

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory stands out as a prestigious center for biomedical research and education located on Long Island's North Shore. Home to eight Nobel laureates and dedicated to fostering curiosity and innovation in life sciences, CSHL is a leading nonprofit research institution. For more details, visit www.cshl.edu.